A detailed history of Cantor Fitzgerald, L. P. transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 334,192 shares of SLN stock, worth $2.3 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares
334,192
Previous 247,966 34.77%
Holding current value
$2.3 Million
Previous $4.71 Million 29.02%
% of portfolio
0.59%
Previous 0.68%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.53 - $21.74 $1.34 Million - $1.87 Million
86,226 Added 34.77%
334,192 $6.08 Million
Q2 2024

Aug 14, 2024

BUY
$18.31 - $23.91 $2.65 Million - $3.45 Million
144,483 Added 139.62%
247,966 $4.71 Million
Q1 2024

May 15, 2024

SELL
$17.39 - $26.25 $752,882 - $1.14 Million
-43,294 Reduced 29.5%
103,483 $2.24 Million
Q4 2023

Feb 14, 2024

SELL
$6.7 - $17.67 $985,677 - $2.6 Million
-147,116 Reduced 50.06%
146,777 $2.55 Million
Q2 2023

Aug 14, 2023

BUY
$4.61 - $7.44 $21,828 - $35,228
4,735 Added 1.64%
293,893 $1.62 Million
Q1 2023

May 15, 2023

SELL
$6.2 - $15.61 $77,698 - $195,624
-12,532 Reduced 4.15%
289,158 $1.79 Million
Q4 2022

Feb 14, 2023

BUY
$9.69 - $17.09 $889,580 - $1.57 Million
91,804 Added 43.74%
301,690 $4.6 Million
Q3 2022

Nov 14, 2022

SELL
$2.65 - $29.85 $4,171 - $46,983
-1,574 Reduced 0.74%
209,886 $2.11 Million
Q2 2022

Aug 15, 2022

BUY
$7.99 - $19.5 $301,502 - $735,832
37,735 Added 21.72%
211,460 $2.51 Million
Q1 2022

May 16, 2022

SELL
$16.5 - $23.89 $1.33 Million - $1.93 Million
-80,794 Reduced 31.74%
173,725 $3.3 Million
Q4 2021

Feb 14, 2022

BUY
$20.61 - $25.71 $5.25 Million - $6.54 Million
254,519 New
254,519 $6.08 Million

Others Institutions Holding SLN

About Silence Therapeutics plc


  • Ticker SLN
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,888,400
  • Market Cap $247M
  • Description
  • Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...
More about SLN
Track This Portfolio

Track Cantor Fitzgerald, L. P. Portfolio

Follow Cantor Fitzgerald, L. P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cantor Fitzgerald, L. P., based on Form 13F filings with the SEC.

News

Stay updated on Cantor Fitzgerald, L. P. with notifications on news.